Publication:
Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment

Placeholder

Organizational Units

Program

KU Authors

Co-Authors

Ibis, Kamuran
Saglam, Sezer
Saglam, Esra Kaytan
Yilmazbayhan, Dilek
Toker, Alper
Ozkan, Berker
Hancer, Veysel S.
Buyukdogan, Murat
Disci, Rian
Pilanci, Kezban Nur

Advisor

Publication Date

2018

Language

English

Type

Journal Article

Journal Title

Journal ISSN

Volume Title

Abstract

Background: To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients. Methods: Tissue CA IX expression was examined after surgical resection in 77 patients who had undergone neoadjuvant treatment. The effects of CA IX overexpression and other clinical factors on disease-free survival and overall survival were investigated. Results: In multivariate analysis, number of neoadjuvant chemotherapy (CT) courses and gender emerged as significant independent predictors for disease-free survival, where administration of 2-3 courses of neoadjuvant chemotherapy (CT) (HR, 3.2 [95% CI 1.3-7.6], p = 0.009) and female gender were associated with poor survival (HR, 3.2 [95% CI 1.3-7.7], p = 0.009). The only significant independent predictor for overall survival was recurrence (HR, 5.6 [95% CI 2.4-12.8], p < 0.001). On the other hand, CA IX overexpression was not associated with disease free survival (p = 0.560) or overall survival (p = 0.799). Discussion: Our results do not suggest a prognostic role for CA IX overexpression in stage III NSCLC patients who received neoadjuvant treatment.

Description

Source:

Pathology Research and Practice

Publisher:

Elsevier

Keywords:

Subject

Pathology

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note

0

Views

0

Downloads

View PlumX Details